ALS

2N Pharma is at the forefront of developing innovative treatments for neurodegenerative diseases like ALS and Parkinson’s. Their drug candidate, Mitometin, targets mitochondrial dysfunction, offering new hope for patients. With significant funding and strategic partnerships, they are reshaping our understanding of these conditions and advancing research in neuro-metabolic diseases.